Current Opinion in Hematology最新文献

筛选
英文 中文
Platelets and platelet-leukocyte interactions in infectious diseases. 传染病中的血小板和血小板-白细胞相互作用。
IF 2.9 3区 医学
Current Opinion in Hematology Pub Date : 2025-09-01 Epub Date: 2025-07-14 DOI: 10.1097/MOH.0000000000000878
Marcelo Miranda Lima de Paula, Renata Tôrres Rêgo Oliveira, Eugenio D Hottz
{"title":"Platelets and platelet-leukocyte interactions in infectious diseases.","authors":"Marcelo Miranda Lima de Paula, Renata Tôrres Rêgo Oliveira, Eugenio D Hottz","doi":"10.1097/MOH.0000000000000878","DOIUrl":"10.1097/MOH.0000000000000878","url":null,"abstract":"<p><strong>Purpose of review: </strong>Platelets are essential effector cells in the immune continuum. Understanding platelet roles during infectious diseases is paramount to understanding pathological and protective immune responses. In this review, we compiled recent data about platelets in immune response to infectious diseases.</p><p><strong>Recent findings: </strong>Platelets recognize and respond to pathogens, including viruses, bacteria and parasites, contributing to the assembly of the immune response. Platelet activation and platelet-leukocyte aggregates formation have been observed in naturally infected humans and in experimental models of diseases. In this review we discuss recent findings on the mechanisms and outcomes of platelet activation and platelet-leukocyte interaction in infectious diseases and response to vaccine. Pathogens may modulate platelet response to escape immune surveillance, but platelets still contribute to host defense. We compiled evidence of platelet mediated-pathological responses, but also their contributions to pathogen clearance. We focused on the participation of platelets in pathophysiological and protective responses in infectious diseases of global impact such as COVID-19, HIV-1, viral hemorrhagic fevers, bacterial sepsis and parasite infections.</p><p><strong>Summary: </strong>Platelets contribute to protective and pathological responses by regulating innate and adaptive immunity through activation, hyperaggregability and directly interacting with pathogens. Even though many mechanisms underlying platelet roles in infectious disease have been revealed, much remains to be investigated.</p>","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"261-269"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144644195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial introduction. 编辑介绍。
IF 2.9 3区 医学
Current Opinion in Hematology Pub Date : 2025-09-01 Epub Date: 2025-07-31 DOI: 10.1097/MOH.0000000000000886
{"title":"Editorial introduction.","authors":"","doi":"10.1097/MOH.0000000000000886","DOIUrl":"https://doi.org/10.1097/MOH.0000000000000886","url":null,"abstract":"","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":"32 5","pages":"v"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144746017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting hemostatic enzymes: from mechanistic insights to therapeutic frontiers. 靶向止血酶:从机制的见解到治疗前沿。
IF 2.9 3区 医学
Current Opinion in Hematology Pub Date : 2025-09-01 Epub Date: 2025-07-14 DOI: 10.1097/MOH.0000000000000884
Rida Zakar, Matthew D Neal, Susan M Shea
{"title":"Targeting hemostatic enzymes: from mechanistic insights to therapeutic frontiers.","authors":"Rida Zakar, Matthew D Neal, Susan M Shea","doi":"10.1097/MOH.0000000000000884","DOIUrl":"10.1097/MOH.0000000000000884","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review examines the enzymatic regulation of coagulation and fibrinolysis, focusing on key players such as thrombin, plasmin, and ADAMTS13. We highlight how dysregulation of these enzymes contributes to thrombotic and hemorrhagic disorders and review emerging diagnostic biomarkers and therapeutic strategies.</p><p><strong>Recent findings: </strong>Recent studies demonstrate the prognostic utility of biomarkers such as thrombin-antithrombin (TAT) and plasmin-α2-antiplasmin (PAP) complexes across critical illnesses including trauma, sepsis, and stroke. Advances in plasmin and thrombin generation assays, enzyme-specific assays, and enzyme-modulating therapies (e.g., factor XI inhibitors and recombinant ADAMTS13) are reshaping approaches to hemostatic balance.</p><p><strong>Summary: </strong>Understanding hemostatic enzymatic regulation offers new avenues for risk stratification, diagnosis, and treatment of coagulation disorders. Although significant progress has been made, challenges remain in translating laboratory findings to clinical practice, necessitating further large-scale validation. Precision-guided enzymatic therapies hold promise for improving outcomes in acute care settings.</p>","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"253-260"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12270332/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144638686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Humanized murine models of platelet function. 人源化小鼠血小板功能模型。
IF 2.9 3区 医学
Current Opinion in Hematology Pub Date : 2025-09-01 Epub Date: 2025-07-11 DOI: 10.1097/MOH.0000000000000879
Javier Menéndez-Pérez, Abigail Ajanel, Robert A Campbell
{"title":"Humanized murine models of platelet function.","authors":"Javier Menéndez-Pérez, Abigail Ajanel, Robert A Campbell","doi":"10.1097/MOH.0000000000000879","DOIUrl":"10.1097/MOH.0000000000000879","url":null,"abstract":"<p><strong>Purpose of review: </strong>In this review, we will describe murine models developed to examine human platelet function.</p><p><strong>Recent findings: </strong>Platelets are critical cells necessary to regulate hemostasis after vessel injury. However, excessive platelet activation can lead to thrombotic complications. Preclinical/translational models are critical in developing therapeutics against platelet activation and to understand mechanistically how platelets function. Researchers have relied on murine models to study platelet function in vivo due to ease of establishing genetic knockouts as well as their lower cost and high throughput nature compared to larger animal models. However, while murine platelets are similar to human based on transcriptomic and proteomic analysis, there are significant differences between the two species, which limits their translation to the human system. To overcome these hurdles, investigators have targeted human platelet genes into the murine genome to express human receptors in mouse platelets. In addition, transfusion models of human platelets into mice have provided valuable insight into human platelet function.</p><p><strong>Summary: </strong>Murine models are a value tool to examine platelet function in hemostasis and thrombosis. Continued focus on developing mouse models where platelets resemble those circulating in humans will offer valuable insight into important pathways, which may be targeted in the future.</p>","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"245-252"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12262182/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144627723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multifaceted roles of CRISPR technology in blood cancer research. CRISPR技术在血癌研究中的多重作用
IF 2.9 3区 医学
Current Opinion in Hematology Pub Date : 2025-09-01 Epub Date: 2025-06-03 DOI: 10.1097/MOH.0000000000000855
Maheswaran Solayappan, Adam Azlan, Kang Zi Khor, Mot Yee Yik, Aswani Jaishanker, Thevendran Ramesh, Mohamed Saleem, Narazah Mohd Yusoff, Emmanuel Jairaj Moses
{"title":"Multifaceted roles of CRISPR technology in blood cancer research.","authors":"Maheswaran Solayappan, Adam Azlan, Kang Zi Khor, Mot Yee Yik, Aswani Jaishanker, Thevendran Ramesh, Mohamed Saleem, Narazah Mohd Yusoff, Emmanuel Jairaj Moses","doi":"10.1097/MOH.0000000000000855","DOIUrl":"10.1097/MOH.0000000000000855","url":null,"abstract":"<p><strong>Purpose of review: </strong>Blood cancers are one of the most common cancers worldwide. These diseases stem from defects in blood components having cytogenetic aberrations and genetic mutations. There have been vast improvements in terms of treatment options and survival outcomes. Nevertheless, due to the clonal nature and heterogeneity of the diseases, the number of cases reported exhibit a rising pattern due to chemoresistance and disease relapse thus posing a healthcare burden. Therefore, the need for more specific forms of targeted therapies is ever-present.</p><p><strong>Recent findings: </strong>CRISPR has emerged as a key player and is the epitome of gene editing technology in this post genomic era. In line with the current trend, numerous studies in blood cancer research have extensively utilized CRISPR-based applications to understand the functional genomics of hematologic malignancies and identify potential therapeutic targets for development of novel therapeutic applications.</p><p><strong>Summary: </strong>The importance of comprehending the utilities of state-of-the-art technologies such as CRISPR for studying hematologic malignancies has never been more apparent and timelier. Therefore, this review attempts to scrutinize the versatility of CRISPR applications which range from functional genomics to immunotherapeutic applications.</p>","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"287-299"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144217632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Platelet Fc gamma RIIA: time to go beyond the unknown. 血小板Fc γ RIIA:时间超越未知。
IF 2.9 3区 医学
Current Opinion in Hematology Pub Date : 2025-09-01 Epub Date: 2025-07-07 DOI: 10.1097/MOH.0000000000000881
Izabella Andrianova, Rattanawan Thubthed, Frederik Denorme
{"title":"Platelet Fc gamma RIIA: time to go beyond the unknown.","authors":"Izabella Andrianova, Rattanawan Thubthed, Frederik Denorme","doi":"10.1097/MOH.0000000000000881","DOIUrl":"10.1097/MOH.0000000000000881","url":null,"abstract":"<p><strong>Purpose of review: </strong>Increasing evidence has shown that immune and thrombotic pathways cooperate to ensure efficient immune and hemostatic functions. Due to their involvement in various cardiovascular and inflammatory conditions, this interplay has gained significant interest, leading to many important discoveries. However, difference between mice and humans have limited the translatability of some of these findings. One key receptor involved in immuno-thrombosis but lacking in mice is the Fc gamma receptor IIA (FcγRIIA).</p><p><strong>Recent findings: </strong>Innovative in-vitro and in-vivo models for anti-PF4 immune disorders have greatly impacted our understanding of the role of FcγRIIA in these disorders and has revealed novel therapeutic strategies with great translational potential. Epideminological studies have hinted at a role for FcγRIIA in cardiovascular diseases; however, conclusive mechanistic studies are currently lacking.</p><p><strong>Summary: </strong>Humanized transgenic FcγRIIA mice have greatly advanced our understanding of the role of FcγRIIA in anti-PF4 immune disorders, immune thrombocytopenia and lupus; however, they have only rarely been used in models of thrombo-inflammation. To improve translation from bench to bedside, inclusion of FcγRIIA transgenic mouse models is encouraged.</p>","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"231-238"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144585716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mesenchymal stromal cells: an update. 间充质间质细胞:一个更新。
IF 2.9 3区 医学
Current Opinion in Hematology Pub Date : 2025-09-01 Epub Date: 2025-07-16 DOI: 10.1097/MOH.0000000000000887
Olivia J Lee, Armand Keating
{"title":"Mesenchymal stromal cells: an update.","authors":"Olivia J Lee, Armand Keating","doi":"10.1097/MOH.0000000000000887","DOIUrl":"10.1097/MOH.0000000000000887","url":null,"abstract":"<p><strong>Purpose of review: </strong>Mesenchymal stromal cells (MSCs) are widely utilized in preclinical and clinical studies, with over 1500 clinical trials, including applications in Covid-19 treatment. This review consolidates recent advances in understanding MSC biology, mechanisms of action, and clinical utility.</p><p><strong>Recent findings: </strong>This review discusses recent progress made in understanding MSC biology, including immunomodulatory mechanisms mediated by microRNAs and long noncoding RNAs. Clinically, MSC therapies have shown promise in treating conditions like Covid-19-associated ARDS and several MSC therapeutic products have been approved. Single-cell analyses have shed light on MSC heterogeneity, revealing tissue-specific and conserved subpopulations influenced by the extracellular matrix. The FDA's updated recommendations on potency assays emphasize a holistic approach to quality control, reinforcing the need for a universal reference standard to improve reproducibility and clinical outcomes. In addition, to better understand their limited success in randomized clinical trials, we highlight the importance of a universal reference standard for MSC potency.</p><p><strong>Summary: </strong>MSCs offer significant therapeutic potential, but addressing challenges in heterogeneity and potency standardization is essential. Advances in understanding their immune properties and clinical applications provide opportunities to refine and expand their use in regenerative medicine.</p>","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"270-278"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144644194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hemostatic abnormalities in acute promyelocytic leukemia: clinical implications and mechanisms. 急性早幼粒细胞白血病的止血异常:临床意义和机制。
IF 2.9 3区 医学
Current Opinion in Hematology Pub Date : 2025-09-01 Epub Date: 2025-07-07 DOI: 10.1097/MOH.0000000000000880
Yohei Hisada, Radhika Gangaraju
{"title":"Hemostatic abnormalities in acute promyelocytic leukemia: clinical implications and mechanisms.","authors":"Yohei Hisada, Radhika Gangaraju","doi":"10.1097/MOH.0000000000000880","DOIUrl":"10.1097/MOH.0000000000000880","url":null,"abstract":"<p><strong>Purpose of review: </strong>Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia. The long-term prognosis for APL is generally more favorable than for other types of acute leukemia due to the use of differentiation therapies. However, early hemorrhagic death remains a significant clinical challenge in APL patients.</p><p><strong>Recent findings: </strong>Real-world studies reveal that the rate of early hemorrhagic death remains high (10-30%) in APL patients in the era of differentiation therapy. APL patients have systemic hemostatic changes including activation of coagulation followed by consumption of coagulation factors, hyperfibrinolysis, and severe thrombocytopenia. Our study found that tissue factor contributes to a bleeding phenotype in mouse models of APL. In-vitro studies suggest that there may be direct or indirect interaction between APL cells and brain endothelial cells.</p><p><strong>Summary: </strong>Predictors of hemorrhagic death in APL are only partially understood. The associations between bleeding and hyperfibrinolysis or thrombocytopenia in APL need to be determined. The interaction between APL cells and brain endothelial cells need to be determined in vivo .</p>","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"239-244"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12240473/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144585715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances on the genetic basis of red cell membrane disorders. 红细胞膜疾病的遗传基础研究进展。
IF 2.9 3区 医学
Current Opinion in Hematology Pub Date : 2025-09-01 Epub Date: 2025-07-04 DOI: 10.1097/MOH.0000000000000883
Mary Risinger, Wenying Zhang, Theodosia A Kalfa
{"title":"Advances on the genetic basis of red cell membrane disorders.","authors":"Mary Risinger, Wenying Zhang, Theodosia A Kalfa","doi":"10.1097/MOH.0000000000000883","DOIUrl":"10.1097/MOH.0000000000000883","url":null,"abstract":"<p><strong>Purpose of review: </strong>The development and widespread use of genetic testing for diagnosis of red blood cell (RBC) membrane disorders and other hereditary hemolytic anemias (HHA) have expanded our understanding of these diseases and revealed additional complexities. We describe here such complexities and make suggestions regarding genotypic/phenotypic evaluation with the goal of early diagnosis of patients with HHA before inappropriate treatment or complications occur.</p><p><strong>Recent findings: </strong>Widespread use of clinical genetic diagnosis in patients, for more than a decade now, has revealed the heterogeneity of RBC membranopathies, even when caused by different variants in the same gene, and sometimes due to the same genetic variant, likely because of genetic modifiers or mutations in other genes encoding for RBC membrane proteins, enzymes, or globins. Many under-recognized diseases are now more easily diagnosed.</p><p><strong>Summary: </strong>Despite complexities in the genetic evaluation of RBC membranopathies, the future holds great promise for timely and accurate diagnosis. Correlation and documentation of genotypic and phenotypic data from affected individuals and family members will allow for improved detection and interpretation of genetic results. The use of such testing in newborns and children with HHA can optimize treatment decisions and explore possibilities for novel targeted or genetic therapies.</p>","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"279-286"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12240464/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144585713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Megakaryocytes as mitochondria factories: potential donors for mitochondria transplantation. 巨核细胞作为线粒体工厂:线粒体移植的潜在供体。
IF 3.1 3区 医学
Current Opinion in Hematology Pub Date : 2025-07-15 DOI: 10.1097/MOH.0000000000000889
Émilie Mercure, Martin Pelletier, Éric Boilard
{"title":"Megakaryocytes as mitochondria factories: potential donors for mitochondria transplantation.","authors":"Émilie Mercure, Martin Pelletier, Éric Boilard","doi":"10.1097/MOH.0000000000000889","DOIUrl":"https://doi.org/10.1097/MOH.0000000000000889","url":null,"abstract":"<p><strong>Purpose of review: </strong>There is an increasing recognition that mitochondria are dynamic regulators of cell fate. Mitochondria transplantation has emerged as a promising therapeutic strategy for conditions ranging from metabolic disorders to neurodegenerative diseases. Thus, there is a growing need for scalable mitochondrial sources for transplantation. We highlight megakaryocytes, best known for their role in platelet production, as a novel and versatile candidate source for mitochondria transplantation.</p><p><strong>Recent findings: </strong>Megakaryocytes are naturally equipped to package and deliver functional mitochondria when producing platelets. Furthermore, MKs can share their mitochondria with neighboring cells in the bone marrow. Given the abundance of mitochondria in megakaryocytes, they may represent an ideal source of mitochondria for transplantation. A better understanding of the role of mitochondria in megakaryocyte heterogeneity and metabolic functions may help harness megakaryocytes for therapeutic transplantation applications.</p><p><strong>Summary: </strong>Megakaryocyte-derived mitochondria transplantation offers a promising avenue for treating metabolic disorders, leveraging existing mechanisms. Future research should address limitations in megakaryocyte biogenesis and heterogeneity, and optimize delivery systems to maximize therapeutic efficacy.</p>","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144638685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信